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were observed. In patient with stomach adenomas, degree of
atrophy increases as the pepsinogen I/pepsinogen II ratio
decreases, the ability of immune cells to produce IL-18 under
the influence of PA stimulates proliferation of cells, including
atypical.
Conclusion: Findings suggest the ability of blood cells to pro-
duce TNFa, IL-18 and IFNc under the influence of polyclonal acti-
vators was higher in patients with stomach adenomas than in
patients with stomach adenocarcinomas. In patients with adeno-
carcinomas the decline in the production of cytokines with both
the proliferative and antiproliferative effects indicates radical
changes in the cytokine-producing capability of immunocompe-
tent cells when malignant neoplasm became mature.
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Background: Tumour-associated macrophages (TAM) derived
from peripheral blood monocytes are a key immune regulatory
component of tumour microenvironment (Qian, Pollard, 2010).
Advanced clinically applicable strategy for TAM targeting is their
functional reprogramming (Wynn et al., 2013). Monocytes/
macrophages are heterogeneous and versatile cells. Two major
macrophage subpopulations with different functions which rep-
resent extreme of a continuum in a universe of activation states,
including classically activated/inflammatory (M1) and alterna-
tively activated/regenerative (M2) macrophages, have long been
recognized (Zhou et al., 2014). CD68 and CD163 are the general
markers of M1 and M2 subsets respectively (Hoene et al., 2015,
Tedesco et al., 2014). However, there are different markers
expressed on surface of monocytes/macrophages that reflected
some special functional activities of these cells. Thus, expression
of CD119(IFN-cR) or CD124(IL-4R) reflects the predisposition to M1
or M2-polarisation by suitable cytokines IFN-c and IL-4 (Tedesco
et al., 2014). The pro-inflammatory marker CD282 (TLR2) is asso-
ciated with antibacterial function. Anti-inflammatory CD36+ cells
take part in scavenging of apoptotic remains and inducing IL-10
production. Although monocytes/macrophages could undergo
their phenotypically/functionally dynamic switch in response to
the microenvironment signals there is some predisposition of
their status in peripheral blood to polarization in tissues. Modula-
tion of monocyte peripheral status before their infiltration is an
attractive target for cancer therapeutic approaches.
The aim is to study phenotypic subsets of peripheral blood
monocytes in breast and gastric cancer patients.
Materials and methods: 8 breast cancer and 8 gastric cancer
patients T1N0-3M0 treated in Tomsk Cancer Institute were
enrolled in investigation. The diagnosis was histologically veri-
fied. Phenotypic features were assessed by flow cytometry using
mAb CD119(IFN-cRa), CD124(IL-4R), CD282 (TLR2), CD36, CD68,
CD163 (BD Pharmingen) before treatment and in 5 days after sur-
gery of tumour.
Results: We found that amounts of monocytes expressing
main surface markers of M-1 or M2-type activation in peripheral
blood in cancer patients wasn’t large: CD68+ and CD163+ cells
were 4.18 ± 3.41% and 7.64 ± 3.75% of whole pool of monocytes
respectively. This finding supports the fact that in general
M1/M2-polarization of monocytes/macrophages occurs in local
tissues by specific micro- environmental conditions [Ambarus
et al., 2012, Zhou et al., 2014]. But high levels of CD119(IFN-cR)+
monocytic cells (87.36 ± 12.08%) in peripheral blood showed that
predisposition to M1-polarization of circulating monocytes exists
in cancer patients, because it’s known IFN-c significantly
increased the fraction of surface CD68 – expressing cells and
down-regulated expression of the M2 markers in vitro [Tedesco
et al., 2014]. Expression of CD124 (IL-4R) was detected only in
26.81 ± 8.11% of monocytes in cancer patients. The subset of
pro-inflammatory CD282+ (TLR2) circulating monocytes
amounted 64.38 ± 9.47% of total count of monocytic cells. Anti-
inflammatory CD36+ monocytes were 35.66 ± 7.00%. It is notewor-
thy this subset was 48.43 ± 8.13% in breast cancer patients and
only 22.88 ± 9.86% in gastric cancer patients (p < 0.05).
On the 5-th day after surgery, we detected decrease in CD282+
cells from 80.90 ± 8.55% to 38.70 ± 9.47% of total monocytes count
in breast cancer patients (p < 0.05). Another noticeable feature of
monocytes pool after operation was increasing of anti-
inflammatory CD36+monocytes as in breast (1.69-fold) and
gastric (1.97 fold) cancer patients.
Conclusion: There were a small accounts of M1 (CD68+) or M2
(CD163+) polarized monocytes in peripheral blood in breast and
gastric cancer patients. INF-c(CD119)+ and CD282(TLR2)+ pro-
inflammatory subsets were dominated in cancer patients. The
high levels of CD36+monocytes was the feature of breast cancer
patients as compared with gastric cancer ones. Surgery removal
of tumour was associated with increasing of CD36+ monocytes
in both breast and gastric cancer and with decreasing of CD282
(TLR2)+ monocytes in breast cancer.
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Melanoma is the most aggressive and dangerous skin cancer.
In 2013 about 23.8% of patients developed III–IV stages of a
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